Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 280

1.

From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.

Hussain SA, Birtle A, Crabb S, Huddart R, Small D, Summerhayes M, Jones R, Protheroe A.

Eur Urol Oncol. 2018 Dec;1(6):486-500. doi: 10.1016/j.euo.2018.05.011. Epub 2018 Jul 2. Review.

PMID:
31158093
2.

Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors.

Abu Zaid M, Dinh PC, Monahan PO, Fung C, El-Charif O, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Cook R, Althouse S, Ardeshir-Rouhani-Fard S, Sesso HD, Huddart R, Mushiroda T, Kubo M, Dolan ME, Einhorn LH, Fossa SD, Travis LB; Platinum Study Group.

J Natl Compr Canc Netw. 2019 May 1;17(5):459-468. doi: 10.6004/jnccn.2018.7109.

PMID:
31085753
3.

Pharmacogenomics in dermatology: tools for understanding gene-drug associations.

Daneshjou R, Huddart R, Klein TE, Altman RB.

Semin Cutan Med Surg. 2019 Mar 1;38(1):E19-E24. doi: 10.12788/j.sder.2019.009.

PMID:
31051019
4.

Are Randomized Controlled Trials Necessary to Establish the Value of Implementing Pharmacogenomics in the Clinic?

Huddart R, Sangkuhl K, Whirl-Carrillo M, Klein TE.

Clin Pharmacol Ther. 2019 Apr 12. doi: 10.1002/cpt.1420. [Epub ahead of print] No abstract available.

PMID:
30977517
5.

Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms.

El Charif O, Mapes B, Trendowski MR, Wheeler HE, Wing C, Dinh PC Jr, Frisina RD, Feldman DR, Hamilton RJ, Vaughn DJ, Fung C, Kollmannsberger C, Mushiroda T, Kubo M, Gamazon ER, Cox NJ, Huddart R, Ardeshir-Rouhani-Fard S, Monahan P, Fossa SD, Einhorn LH, Travis LB, Dolan ME.

Clin Cancer Res. 2019 Apr 5. doi: 10.1158/1078-0432.CCR-18-3179. [Epub ahead of print]

PMID:
30952644
6.

MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer.

Walker AK, Karaszi K, Valentine H, Strauss VY, Choudhury A, McGill S, Wen K, Brown MD, Ramani V, Bhattarai S, Teo MTW, Yang L, Myers KA, Deshmukh N, Denley H, Browning L, Love SB, Iyer G, Clarke NW, Hall E, Huddart R, James ND, Hoskin PJ, West CML, Kiltie AE.

Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):809-818. doi: 10.1016/j.ijrobp.2019.03.015. Epub 2019 Mar 15.

7.

Positron Emission Tomography-Positive Post-Chemotherapy Seminoma Masses: Time to Reevaluate the Role of Radiotherapy?

Murthy V, Johnny C, Huddart R.

J Clin Oncol. 2019 Apr 10;37(11):937-938. doi: 10.1200/JCO.18.01991. Epub 2019 Feb 27. No abstract available.

PMID:
30811289
8.

Comparison of prostate delineation on multimodality imaging for MR-guided radiotherapy.

Pathmanathan AU, McNair HA, Schmidt MA, Brand DH, Delacroix L, Eccles CL, Gordon A, Herbert T, van As NJ, Huddart RA, Tree AC.

Br J Radiol. 2019 Mar;92(1095):20180948. doi: 10.1259/bjr.20180948. Epub 2019 Jan 24.

PMID:
30676772
9.

PharmGKB summary: Ondansetron and tropisetron pathways, pharmacokinetics and pharmacodynamics.

Huddart R, Altman RB, Klein TE.

Pharmacogenet Genomics. 2019 Jun;29(4):91-97. doi: 10.1097/FPC.0000000000000369. No abstract available.

PMID:
30672837
10.

Standardized Biogeographic Grouping System for Annotating Populations in Pharmacogenetic Research.

Huddart R, Fohner AE, Whirl-Carrillo M, Wojcik GL, Gignoux CR, Popejoy AB, Bustamante CD, Altman RB, Klein TE.

Clin Pharmacol Ther. 2019 May;105(5):1256-1262. doi: 10.1002/cpt.1322. Epub 2019 Jan 21.

PMID:
30506572
11.

BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004).

Kelly JD, Tan WS, Porta N, Mostafid H, Huddart R, Protheroe A, Bogle R, Blazeby J, Palmer A, Cresswell J, Johnson M, Brough R, Madaan S, Andrews S, Cruickshank C, Burnett S, Maynard L, Hall E; BOXIT Investigators.

Eur Urol. 2019 Apr;75(4):593-601. doi: 10.1016/j.eururo.2018.09.020. Epub 2018 Sep 29.

PMID:
30279015
12.

PharmGKB summary: oxycodone pathway, pharmacokinetics.

Huddart R, Clarke M, Altman RB, Klein TE.

Pharmacogenet Genomics. 2018 Oct;28(10):230-237. doi: 10.1097/FPC.0000000000000351. No abstract available.

PMID:
30222708
13.

Magnetic Resonance-guided Radiotherapy - Can We Justify More Expensive Technology?

Tree AC, Huddart R, Choudhury A.

Clin Oncol (R Coll Radiol). 2018 Nov;30(11):677-679. doi: 10.1016/j.clon.2018.08.013. Epub 2018 Sep 11. No abstract available.

PMID:
30217480
14.

Circulating Tumour DNA in Muscle-Invasive Bladder Cancer.

Tan MP, Attard G, Huddart RA.

Int J Mol Sci. 2018 Aug 29;19(9). pii: E2568. doi: 10.3390/ijms19092568. Review.

15.

Salvage Chemotherapy With Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin for Relapsed Germ Cell Cancer.

McKenzie HS, Mead G, Huddart R, White JD, Rustin GJS, Hennig IM, Cozens K, Cross N, Bowers M, Wheater MJ.

Clin Genitourin Cancer. 2018 Dec;16(6):458-465.e2. doi: 10.1016/j.clgc.2018.07.006. Epub 2018 Jul 17.

PMID:
30115544
16.

ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up.

Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, Clarke N, Cohn-Cedermark G, Daugaard G, Dieckmann KP, Fizazi K, Fosså S, Germa-Lluch JR, Giannatempo P, Gietema JA, Gillessen S, Haugnes HS, Heidenreich A, Hemminki K, Huddart R, Jewett MAS, Joly F, Lauritsen J, Lorch A, Necchi A, Nicolai N, Oing C, Oldenburg J, Ondruš D, Papachristofilou A, Powles T, Sohaib A, Ståhl O, Tandstad T, Toner G, Horwich A.

Ann Oncol. 2018 Aug 1;29(8):1658-1686. doi: 10.1093/annonc/mdy217.

PMID:
30113631
17.

Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie?

Thompson MK, Poortmans P, Chalmers AJ, Faivre-Finn C, Hall E, Huddart RA, Lievens Y, Sebag-Montefiore D, Coles CE.

Br J Cancer. 2018 Aug;119(4):389-407. doi: 10.1038/s41416-018-0201-z. Epub 2018 Jul 31. Review.

18.

Dose-limiting Urinary Toxicity With Pembrolizumab Combined With Weekly Hypofractionated Radiation Therapy in Bladder Cancer.

Tree AC, Jones K, Hafeez S, Sharabiani MTA, Harrington KJ, Lalondrelle S, Ahmed M, Huddart RA.

Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1168-1171. doi: 10.1016/j.ijrobp.2018.04.070. Epub 2018 May 4.

19.

Large-scale Analysis Demonstrates Familial Testicular Cancer to have Polygenic Aetiology.

Loveday C, Law P, Litchfield K, Levy M, Holroyd A, Broderick P, Kote-Jarai Z, Dunning AM, Muir K, Peto J, Eeles R, Easton DF, Dudakia D, Orr N, Pashayan N; UK Testicular Cancer Collaboration, The PRACTICAL Consortium, Reid A, Huddart RA, Houlston RS, Turnbull C.

Eur Urol. 2018 Sep;74(3):248-252. doi: 10.1016/j.eururo.2018.05.036. Epub 2018 Jun 21.

20.

Adjuvant Therapy for Stage IB Germ Cell Tumors: One versus Two Cycles of BEP.

Huddart RA, Reid AM.

Adv Urol. 2018 Apr 2;2018:8781698. doi: 10.1155/2018/8781698. eCollection 2018. Review.

21.

Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System).

Panebianco V, Narumi Y, Altun E, Bochner BH, Efstathiou JA, Hafeez S, Huddart R, Kennish S, Lerner S, Montironi R, Muglia VF, Salomon G, Thomas S, Vargas HA, Witjes JA, Takeuchi M, Barentsz J, Catto JWF.

Eur Urol. 2018 Sep;74(3):294-306. doi: 10.1016/j.eururo.2018.04.029. Epub 2018 May 10. Review.

PMID:
29755006
22.

Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.

Kerns SL, Fung C, Monahan PO, Ardeshir-Rouhani-Fard S, Abu Zaid MI, Williams AM, Stump TE, Sesso HD, Feldman DR, Hamilton RJ, Vaughn DJ, Beard C, Huddart RA, Kim J, Kollmannsberger C, Sahasrabudhe DM, Cook R, Fossa SD, Einhorn LH, Travis LB; Platinum Study Group.

J Clin Oncol. 2018 May 20;36(15):1505-1512. doi: 10.1200/JCO.2017.77.0735. Epub 2018 Apr 4.

23.

SPIRE - combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial.

Crabb S, Danson SJ, Catto JWF, McDowell C, Lowder JN, Caddy J, Dunkley D, Rajaram J, Ellis D, Hill S, Hathorn D, Whitehead A, Kalevras M, Huddart R, Griffiths G.

Trials. 2018 Apr 3;19(1):216. doi: 10.1186/s13063-018-2586-7.

24.

Validation of loci at 2q14.2 and 15q21.3 as risk factors for testicular cancer.

Loveday C, Litchfield K, Levy M, Holroyd A, Broderick P, Kote-Jarai Z, Dunning AM, Muir K, Peto J, Eeles R, Easton DF, Dudakia D, Orr N, Pashayan N, Reid A, Huddart RA, Houlston RS, Turnbull C.

Oncotarget. 2017 Dec 7;9(16):12630-12638. doi: 10.18632/oncotarget.23117. eCollection 2018 Feb 27.

25.

PharmGKB summary: clobazam pathway, pharmacokinetics.

Huddart R, Leeder JS, Altman RB, Klein TE.

Pharmacogenet Genomics. 2018 Apr;28(4):110-115. doi: 10.1097/FPC.0000000000000327. No abstract available.

26.

Large-scale Sequencing of Testicular Germ Cell Tumour (TGCT) Cases Excludes Major TGCT Predisposition Gene.

Litchfield K, Loveday C, Levy M, Dudakia D, Rapley E, Nsengimana J, Bishop DT, Reid A, Huddart R, Broderick P, Houlston RS, Turnbull C.

Eur Urol. 2018 Jun;73(6):828-831. doi: 10.1016/j.eururo.2018.01.021. Epub 2018 Feb 9.

PMID:
29433971
27.

IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance.

Selfe J, Goddard NC, McIntyre A, Taylor KR, Renshaw J, Popov SD, Thway K, Summersgill B, Huddart RA, Gilbert DC, Shipley JM.

J Pathol. 2018 Feb;244(2):242-253. doi: 10.1002/path.5008. Epub 2018 Jan 10.

28.

COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.

Crabb SJ, Martin K, Abab J, Ratcliffe I, Thornton R, Lineton B, Ellis M, Moody R, Stanton L, Galanopoulou A, Maishman T, Geldart T, Bayne M, Davies J, Lamb C, Popat S, Joffe JK, Nutting C, Chester J, Hartley A, Thomas G, Ottensmeier C, Huddart R, King E.

Eur J Cancer. 2017 Dec;87:75-83. doi: 10.1016/j.ejca.2017.09.033. Epub 2017 Nov 10.

29.

Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer.

Reis Ferreira M, Khan A, Thomas K, Truelove L, McNair H, Gao A, Parker CC, Huddart R, Bidmead M, Eeles R, Khoo V, van As NJ, Hansen VN, Dearnaley DP.

Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1234-1242. doi: 10.1016/j.ijrobp.2017.07.041. Epub 2017 Aug 2.

30.

Mendelian randomisation analysis provides no evidence for a relationship between adult height and testicular cancer risk.

Levy M, Hall D, Sud A, Law P, Litchfield K, Dudakia D, Haugen TB, Karlsson R, Reid A, Huddart RA, Grotmol T, Wiklund F, Houlston RS, Turnbull C.

Andrology. 2017 Sep;5(5):914-922. doi: 10.1111/andr.12388. Epub 2017 Aug 13.

31.

Positron Emission Tomography Scanning for Recurrent Bladder Cancer.

Wilson JM, Huddart RA.

Eur Urol Focus. 2016 Jun;2(2):219-220. doi: 10.1016/j.euf.2016.02.002. Epub 2016 Mar 19.

PMID:
28723538
32.

Upfront Docetaxel in the Post-STAMPEDE World: Lessons from an Early Evaluation of Non-trial Usage in Hormone-Sensitive Prostate Cancer.

Patrikidou A, Uccello M, Tree A, Parker C, Attard G, Eeles R, Khoo V, van As N, Huddart R, Dearnaley D, Reid A.

Clin Oncol (R Coll Radiol). 2017 Oct;29(10):e174-e175. doi: 10.1016/j.clon.2017.06.006. Epub 2017 Jun 23. No abstract available.

PMID:
28652092
33.

Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor.

Litchfield K, Levy M, Orlando G, Loveday C, Law PJ, Migliorini G, Holroyd A, Broderick P, Karlsson R, Haugen TB, Kristiansen W, Nsengimana J, Fenwick K, Assiotis I, Kote-Jarai Z, Dunning AM, Muir K, Peto J, Eeles R, Easton DF, Dudakia D, Orr N, Pashayan N; UK Testicular Cancer Collaboration; PRACTICAL Consortium, Bishop DT, Reid A, Huddart RA, Shipley J, Grotmol T, Wiklund F, Houlston RS, Turnbull C.

Nat Genet. 2017 Jul;49(7):1133-1140. doi: 10.1038/ng.3896. Epub 2017 Jun 12.

34.

Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment.

Hafeez S, McDonald F, Lalondrelle S, McNair H, Warren-Oseni K, Jones K, Harris V, Taylor H, Khoo V, Thomas K, Hansen V, Dearnaley D, Horwich A, Huddart R.

Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):115-122. doi: 10.1016/j.ijrobp.2017.01.239. Epub 2017 Feb 9. Erratum in: Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):532-533.

35.

Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy.

Huddart RA, Birtle A, Maynard L, Beresford M, Blazeby J, Donovan J, Kelly JD, Kirkbank T, McLaren DB, Mead G, Moynihan C, Persad R, Scrase C, Lewis R, Hall E.

BJU Int. 2017 Nov;120(5):639-650. doi: 10.1111/bju.13900. Epub 2017 May 29.

36.

R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology.

Verkooijen HM, Kerkmeijer LGW, Fuller CD, Huddart R, Faivre-Finn C, Verheij M, Mook S, Sahgal A, Hall E, Schultz C.

Front Oncol. 2017 Apr 3;7:59. doi: 10.3389/fonc.2017.00059. eCollection 2017.

37.

Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer.

Jones RJ, Hussain SA, Protheroe AS, Birtle A, Chakraborti P, Huddart RA, Jagdev S, Bahl A, Stockdale A, Sundar S, Crabb SJ, Dixon-Hughes J, Alexander L, Morris A, Kelly C, Stobo J, Paul J, Powles T.

J Clin Oncol. 2017 Jun 1;35(16):1770-1777. doi: 10.1200/JCO.2016.70.7828. Epub 2017 Apr 12.

PMID:
28402747
38.

A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3).

Shamash J, Sarker SJ, Huddart R, Harland S, Joffe JK, Mazhar D, Birtle A, White J, Chowdhury K, Wilson P, Marshall MR, Vinnicombe S.

Ann Oncol. 2017 Jun 1;28(6):1333-1338. doi: 10.1093/annonc/mdx071.

PMID:
28327896
39.

The National Institute for Health and Care Excellence (NICE) Guidance on Bladder Cancer; a Step in the Right Direction?

Trainor S, Choudhury A, Huddart R, Kiltie AE, Kockelbergh R, Turner W, Birtle A, Crabb SJ.

Clin Oncol (R Coll Radiol). 2017 Jun;29(6):344-347. doi: 10.1016/j.clon.2017.01.040. Epub 2017 Feb 9. No abstract available.

PMID:
28190637
40.

The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004).

Choudhury A, West CM, Porta N, Hall E, Denley H, Hendron C, Lewis R, Hussain SA, Huddart R, James N.

Br J Cancer. 2017 Feb 28;116(5):649-657. doi: 10.1038/bjc.2017.2. Epub 2017 Jan 26.

41.

VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland.

Hussain SA, Ansari J, Huddart R, Power DG, Lyons J, Wylie J, Vilarino-Varlela M, Elander NO, McMenemin R, Pickering LM, Faust G, Chauhan S, Jackson RJ.

Int J Oncol. 2017 Mar;50(3):768-772. doi: 10.3892/ijo.2017.3847. Epub 2017 Jan 13.

42.

Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.

Powles T, Huddart RA, Elliott T, Sarker SJ, Ackerman C, Jones R, Hussain S, Crabb S, Jagdev S, Chester J, Hilman S, Beresford M, Macdonald G, Santhanam S, Frew JA, Stockdale A, Hughes S, Berney D, Chowdhury S.

J Clin Oncol. 2017 Jan;35(1):48-55. Epub 2016 Oct 28.

PMID:
28034079
43.

Rare disruptive mutations in ciliary function genes contribute to testicular cancer susceptibility.

Litchfield K, Levy M, Dudakia D, Proszek P, Shipley C, Basten S, Rapley E, Bishop DT, Reid A, Huddart R, Broderick P, Castro DG, O'Connor S, Giles RH, Houlston RS, Turnbull C.

Nat Commun. 2016 Dec 20;7:13840. doi: 10.1038/ncomms13840.

44.

The present and future of serum diagnostic tests for testicular germ cell tumours.

Murray MJ, Huddart RA, Coleman N.

Nat Rev Urol. 2016 Dec;13(12):715-725. doi: 10.1038/nrurol.2016.170. Epub 2016 Oct 18. Review.

PMID:
27754472
45.

The delineation of intraprostatic boost regions for radiotherapy using multimodality imaging.

Pathmanathan AU, Alexander EJ, Huddart RA, Tree AC.

Future Oncol. 2016 Nov;12(21):2495-2511. Epub 2016 Jun 20. Review.

PMID:
27322113
46.

Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.

Sternberg C, Armstrong A, Pili R, Ng S, Huddart R, Agarwal N, Khvorostenko D, Lyulko O, Brize A, Vogelzang N, Delva R, Harza M, Thanos A, James N, Werbrouck P, Bögemann M, Hutson T, Milecki P, Chowdhury S, Gallardo E, Schwartsmann G, Pouget JC, Baton F, Nederman T, Tuvesson H, Carducci M.

J Clin Oncol. 2016 Aug 1;34(22):2636-43. doi: 10.1200/JCO.2016.66.9697. Epub 2016 Jun 13.

47.

The genomic landscape of testicular germ cell tumours: from susceptibility to treatment.

Litchfield K, Levy M, Huddart RA, Shipley J, Turnbull C.

Nat Rev Urol. 2016 Jul;13(7):409-19. doi: 10.1038/nrurol.2016.107. Epub 2016 Jun 14. Review.

PMID:
27296647
48.

Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder.

Hafeez S, Horwich A, Omar O, Mohammed K, Thompson A, Kumar P, Khoo V, Van As N, Eeles R, Dearnaley D, Huddart R.

Br J Cancer. 2016 Jun 14;114(12):e24. doi: 10.1038/bjc.2016.132. Epub 2016 May 26. No abstract available.

49.

Polygenic susceptibility to testicular cancer: implications for personalised health care.

Litchfield K, Mitchell JS, Shipley J, Huddart R, Rajpert-De Meyts E, Skakkebæk NE, Houlston RS, Turnbull C.

Br J Cancer. 2016 Jun 14;114(12):e22. doi: 10.1038/bjc.2016.136. Epub 2016 May 26. No abstract available.

50.

Prospective Study Delivering Simultaneous Integrated High-dose Tumor Boost (≤70 Gy) With Image Guided Adaptive Radiation Therapy for Radical Treatment of Localized Muscle-Invasive Bladder Cancer.

Hafeez S, Warren-Oseni K, McNair HA, Hansen VN, Jones K, Tan M, Khan A, Harris V, McDonald F, Lalondrelle S, Mohammed K, Thomas K, Thompson A, Kumar P, Dearnaley D, Horwich A, Huddart R.

Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1022-30. doi: 10.1016/j.ijrobp.2015.12.379. Epub 2016 Jan 6.

Supplemental Content

Loading ...
Support Center